Hematology News

ASH awarded $150,000 each to eight investigators through the society’s bridge grant program, designed to sustain promising hematologic research proposals that are not funded through NIH.

A strategy that combines the assessment of clinical probability, D-dimer measurement, compression ultrasonography and CT pulmonary angiography safely and effectively diagnoses pulmonary embolism in pregnant women, according to findings published in Annals of Internal Medicine.

Oct. 13 is World Thrombosis Day, part of a campaign to raise awareness about the condition, including its causes, risk factors, symptoms, and prevention and treatment strategies.

The FDA approved ID CORE XT, a molecular-based assay, to be used to determine blood compatibility prior to blood transfusions.

The FDA approved inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, according to the agent’s manufacturer.

Adolescents with sickle cell disease who received visits and text messages from community health workers reported improved health-related quality of life, according to results of a two-site randomized controlled feasibility study.

The FDA expanded the approval emicizumab-kxwh to include routine prophylaxis to prevent or reduce the frequency of bleeding episodes among patients with hemophilia A without factor VIII inhibitors.

Extended and continuous combined oral contraceptive use was associated with a slightly elevated, but potentially clinically insignificant risk for venous thromboembolism compared with traditional cyclic use, according to research published in JAMA Internal Medicine.

The FDA awarded more than $18 million in grants over the next 4 years to fund clinical trials of medical products intended to treat patients with rare diseases.

Antiphospholipid syndrome occurred following treatment with pembrolizumab for unresectable, stage IIIB melanoma, according to a research letter.